Safety and efficacy of BAY 94–9027, an extended‐half‐life factor VIII, during minor surgical procedures in patients with severe haemophilia A-Reference-Cited by-同舟云学术

Safety and efficacy of BAY 94–9027, an extended‐half‐life factor VIII, during minor surgical procedures in patients with severe haemophilia A

Published:2021-05-03 Issue:4 Volume:27 Page:
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Santagostino Elena¹^ORCID,Lalezari Shadan²³,Reding Mark T.⁴^ORCID,Ducore Jonathan⁵,Ng Heng Joo⁶,Poulsen Lone H.⁷,Michaels Lisa A.⁸,Linardi Camila⁸^ORCID

Affiliation:

1. Foundation IRCCS Ca’ Granda Maggiore Hospital Policlinico A. Bianchi Bonomi Hemophilia and Thrombosis Center Milan Italy

2. Israel National Hemophilia Center, Chaim Sheba Medical Center Tel Hashomer Israel

3. Sackler School of Medicine Tel‐Aviv University Tel Hashomer Israel

4. Center for Bleeding and Clotting Disorders University of Minnesota Medical Center Minneapolis MN USA

5. Hemophilia Treatment Center UC Davis Medical Center Sacramento CA USA

6. Department of Haematology Singapore General Hospital Singapore

7. The Haemophilia Centre Aarhus University Hospital Aarhus Denmark

8. Bayer Whippany NJ USA

Funder

Bayer HealthCare

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14319

Reference10 articles.

1. Invasive procedures and minor surgery in factor VII deficiency

2. Phase I study of BAY 94‐9027, a PEG ylated B‐domain‐deleted recombinant factor VIII with an extended half‐life, in subjects with hemophilia A

3. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII

4. Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial

5. PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review;Drugs in R&D;2024-08-20

2. Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12–<18 Years at Enrolment into PROTECT VIII;Acta Haematologica;2024-04-23

3. Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A;Blood Reviews;2023-12

4. Hemostatic cover in orthopedic surgery;Blood Coagulation & Fibrinolysis;2023-06

5. Perioperative hemostasis for patients with hemophilia;Hematology;2022-12-09